key: cord-0900824-fubgsrsr
authors: Patel, Nimish; Bouchard, Jeannette; Oliver, Meredith B.; Badowski, Melissa E.; Carreno, Joseph J.
title: Early clinical trial data and real‐world assessment of COVID‐19 vaccines: Insights from the Society of Infectious Diseases Pharmacists
date: 2021-10-24
journal: Pharmacotherapy
DOI: 10.1002/phar.2622
sha: 3e7ce63a478924a7f6e3966037ad65eecf036366
doc_id: 900824
cord_uid: fubgsrsr

As of August 2021, there were three COVID‐19 vaccines available in the United States for the prevention of coronavirus 2019 (COVID‐19). The purpose of this narrative review is to examine the early experience from the Emergency Use Authorization (EUA) of BNT162b2 (Pfizer, Inc./BioNTech), mRNA‐1273 (Moderna, Inc.), and Ad26.COV2.S (Johnson and Johnson/Janssen Global Services, LLC) through July 2021. The EUA data from the clinical trials have largely been corroborated by real‐world effectiveness investigations post‐authorization. These studies indicate that immunity is obtained within 2 weeks post‐vaccination and may endure for 6 months. The immunity conferred by the vaccines may also be effective against SARS‐CoV‐2 variants of concern. Additionally, populations not included in the emergency use authorization studies may also benefit from vaccination. This look back at the initial clinical experience can be used by the global community to inform and develop COVID‐19 vaccine programs.

TA B L E 1 Late-stage clinical trials of COVID-19 vaccines (BNT162b2, mRNA-1273, and Ad26.COV2.S) with emergency use authorization • Age ≥18 years • Good/stable health • Significant acute illness • Temperature ≥38.0 C • Allergy or anaphylaxis or other serious adverse reaction to vaccines or excipients • Abnormal function of immune system • Receipt or planning to receive intravenous immunoglobulin within previous 3 months or blood products in the 4 months before study • Persons who were pregnant or breastfeeding • Coexisting conditions that increased risk of severe COVID-19

Abbreviations: P, placebo; RT-PCR, reverse transcriptase-polymerase chain reaction; V, vaccine; VE, vaccine efficacy. a Fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period (or within 4 days before or after symptoms) that was positive for SARS-CoV-2 by nucleic acid amplification-based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test). b Calculated from EUA materials. c At least two of the following symptoms: fever (temperature ≥38℃), chills, myalgia, headache, sore throat, or new olfactory or taste disorder, or as occurring in those who had at least one respiratory sign or symptom and at least one nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if the participant was hospitalized) that was positive for SARS-CoV-2 by reverse transcriptase-polymerase chain reaction (RT-PCR) test. d Measured within 7 days of intramuscular injection. From VRBPAC data. e Mild COVID-19 defined as a SARS-CoV-2-positive RT-PCR or molecular test result from any available respiratory tract sample (eg, nasal swab sample, sputum sample, throat swab sample, saliva sample) or other sample AND One of the following symptoms: fever, sore throat, malaise, headache, myalgia, gastrointestinal symptoms, cough, chest congestion, runny nose, wheezing, skin rash, eye irritation or discharge, or chills, without shortness of breath or dyspnea. Moderate COVID defined as positive SARS-CoV-2 test as above AND any 1 new or worsening sign AND any new or worsening symptom. Severe/ critical COVID-19 defined as positive SARS-CoV-2 test as above AND clinical signs at rest indicative of severe systemic illness, respiratory failure, evidence of shock, significant acute renal, hepatic, or neurologic dysfunction, admission to the ICU, or death. f Calculated from EUA materials.

Prior to being available for routine clinical use, BNT162b2, mRNA-1273, and Ad26.COV2.S, each underwent review by the United States Food and Drug Administration (FDA) using the Emergency Use Authorization (EUA) mechanism. If a drug receives an EUA, the FDA may allow the use of unapproved medical products, such as the COVID-19 vaccine, if certain criteria are met which include no adequate, approved, and available alternatives. 1 Specific to vaccine EUA, all safety data collected from phase 1 and 2 vaccine studies must be submitted and safety data from phase 3 studies must include a minimum of 2-month follow-up data for at least half of the study population. 1 Furthermore, at least 3000 vaccine recipients must be followed for at least 1 month after completion of the full vaccine schedule to assess all clinical and serious adverse events. In addition to demonstrating efficacy, the point estimate for efficacy must be ≥50% and the lower-bound of the appropriately adjusted confidence interval must be >30%. 2

Outcomes Efficacy Safety Pain at injection site was common after the first dose, while systemic reactogenicity was more common after the second dose in both the younger and older vaccine recipients. Mild-moderate local reactions tended to subside within 1-2 days. Fatigue, headache, and fever were the most common systemic reactions reported after the second dose of the vaccine. Fever and chills were typically observed within the first 1-2 days after vaccination and resolved shortly after.

Younger vaccine recipients were more likely to take an antipyretic or pain medication (28% after first dose; 45% after second dose) than older recipients (20% after first dose; 38% after second dose) when compared to the placebo group (10%-14% after either dose).

mRNA-1273 was evaluated in a two-dose vaccine series administered intramuscularly 28 days apart in 30,420 participants (15,210 in each group). 5 The primary efficacy endpoint was COVID-19 (defined as RT-PCR positive SARS-CoV-2 with COVID-19 symptoms, Table 1) at least 14 days after the second injection in participants who were SARS-CoV-2 seronegative at baseline. Similar to BNT162b2, a cutoff date of November 25, 2020 occurred in order to provide at least 2 months of safety data after the second dose.

In this study, COVID-19 was more common in the placebo group compared with the mRNA-1273 group ( In summary, three vaccines, BNT162b2, mRNA-1273, and

Ad26.COV2.S, met the FDA pre-specified criteria for vaccine efficacy. Although there are some numerical differences between these vaccines, direct comparison between trials may not be possible due to differences in study design, SARS-CoV-2 strains, prevalence, and transmission dynamics. These items have been thoroughly reviewed elsewhere. 7 The remainder of this review examines these and additional factors to consider when interpreting COVID-19 vaccine studies conducted outside of randomized controlled trials.

Real-world data should also be considered to determine effec- (Table 2) . A retrospective cohort study of asymptomatic individuals screened during preprocedural testing found that vaccination decreased relative risk of SARS-CoV-2 any time after the second dose. 11 Another study found that vaccination decreased the incidence rate ratios for SARS-CoV-2 infection, asymptomatic SARS-CoV-2, and COVID-19 (or any SARS-CoV-2 after known exposure) in asymptomatic hospital workers. 13 In a different multistate, prospective cohort study of essential and frontline workers vaccine efficacy (95% CI) was estimated to be 91% (73%-97%) for reducing combined COVID-19 and asymptomatic SARS-CoV-2. 12 Together, the results of these studies indicate that BNT162b2 and mRNA-1273 are likely effective at reducing asymptomatic SARS-CoV-2, a major contributor of COVID-19 spread.

Of note, while not a real-world study, Ad26.COV2.S was found to prevent asymptomatic infection in clinical trials. 6 It is also important to note that these studies were conducted prior to any meaningful effect of waning immunity or variants (see General Considerations

for Immunity Post-Vaccination and Variants).

There are several important caveats to interpreting these data. In contrast to randomized controlled trials, these observational studies have many sources of heterogeneity. The first factor that clinicians should consider is the lack of uniform study design. 7 severe COVID-19, hospitalization, and death) also differed between studies. Additionally, differences between which tests were used, which symptoms were assessed, and regional hospitalization patterns can also influence the interpretation of these data.

Other considerations include the study population being evaluated. 7 Populations with a high proportion of individuals in publicfacing careers (eg, healthcare, food distribution) likely have a higher level of community exposure to SARS-CoV-2 than individuals who can shelter in place with minimal exposure. As a result, the incidence of SARS-CoV-2 estimates may be heterogeneous between those with public-facing exposure versus those without. Despite these limitations, it appears that the real-world effectiveness of these vaccines is like that which was observed in clinical trials.

Safety is another large concern among the public. In response,

lished the V-safe adverse event monitoring system. 16 It should be acknowledged that use of Ad26.COV2.S was briefly paused in the United States after cases of thrombosisthrombocytopenia syndrome (TTS) were observed. TTS is characterized by acute blood clots and low platelets in patients with no recent exposure to heparin 19 If not recognized or treated in a timely manner, TTS can be severely disabling and sometimes fatal. 19 At the time of the pause, the vaccine had already been administered in over 6.5 million individuals. It is unclear whether the occurrence of TTS among Ad26.COV2.S was greater than the expected rate in the general population. The median age of TTS cases was 40 and primarily occurred among women. Nonetheless, the FDA and CDC recommended resuming vaccine administration, and the exceptionally low risk of TTS was outweighed by the benefit of the vaccine. Additionally, the CDC recommend that women younger than 50 years old should especially be aware of their increased risk for TTS. 19 Myocarditis after vaccination has also been observed. These concerns were initially highlighted in a case series of seven males ages 

The data from both clinical trials and real-world settings are promis- infection. 26, 27 The robust immune response with vaccination is starkly con- 

At the time of publication, two vaccine administration strategies have evolved for vaccines requiring two doses: the standard method and the delayed second dose method (DSDM). The standard method consists of following the recommended intervals outlined by clinical trials. DSDM allows for second doses at a longer interval than was evaluated in clinical trials. The United Kingdom (UK) was the first country to implement the DSDM with BNT162b2. 29 Since then, other countries around the world adopted DSDM due to vaccine availability concerns. 30 The theoretical basis of the DSDM with BNT162b2 stems from extrapolation of clinical trial data from 15 to 21 days post one dose.

In this window, BNT162b2 had a vaccine efficacy (95% CI) of 89%

(52%-97%). 4 When considering these estimates, there is mathematical rationale for vaccinating more people with one dose as compared to less people with two doses. However, risks associated with DSDM include suboptimal individual protection and increased genetic pressure for variants.

Modeling studies have provided some insight into the DSDM.

An agent-based model suggested delaying the second dose of BNT162b2 was advantageous if immunity remained stable after one dose. 30 Another simulation revealed that the impact of DSDM on mortality was lessened if vaccination rate was high but vaccine efficacy was low. 31 However, sequential combination of standard dosing in those >65 years followed by DSDM in those remaining may result in decreased societal mortality when vaccine efficacy is high.

These data are limited by the fact that these simulations use estimates of vaccine effectiveness following one dose, do not consider the potential for lower efficacy (<70%) and do not uniformly account for immune decay over time.

Knowing which patients have the lowest risk of waning immunity following the first dose would allow for a risk-stratified implementation of DSDM. One potential low-risk category would be patients who have been immunologically primed with a previous SARS-CoV-2 infection. 28 One dose may be comparable with a full vaccination series for these individuals. 32, 33 In one study, a single dose of BNT162b2 or mRNA-1273 produced higher median reciprocal 99% inhibitory dose virus neutralization titers in those with previous SARS-CoV-2 infection (40, 960, 40, 960 , and 80 for those with previous asymptomatic SARS-CoV-2, previous COVID-19, and antibody negative, respectively;

p < 0.001). 32 Another study found that the 95% confidence interval for interval of the percentage of binding that was blocked by antibodies was higher in healthcare workers with a history of SARS-CoV-2 within 60 days (96.0%-97.0%) compared to those without infection (49.6%-66.2%) after one dose. 33 These data suggest that those who have been previously infected with SARS-CoV-2 may be ideal candidates for DSDM, especially within 60 days of infection. 33 The DSDM method, despite original controversy, has been demonstrated in modeling to potentially provide benefit under certain conditions. Coupling the modeling predictions with data on vaccine-induced responses in varying patient populations will allow for more appropriate vaccine administration planning. For a country with high vaccination rates, the DSDM may not provide benefits.

However, in countries with lower vaccination rates, during infection surges, and for specific populations, the DSDM or a risk-stratified variation of this may be appropriate.

Variants of concern (VOC) are SARS-CoV-2 with altered genetic sequences that may increase transmissibility, morbidity, and mortality associated with infection. There are numerous variants of concern identified at different points within the pandemic including but not limited to Alpha (previously B. minimally impacted by Alpha (Table 3) . 35, 36 In contrast, sera of all three vaccines have reduced antibody neutralization efficacy against Beta and Delta. [35] [36] [37] [38] [39] [40] These data are intriguing in that they demonstrate the potential impact of variants on immunity but should be interpreted with caution as in vitro data do not always correspond to in vivo response. Investigators have posited that reduced titers are unlikely to translate to clinical relevance because the resultant titers were above the minimum pseudovirus-neutralizing antibody titer (1:50) that was associated with partial protection in animal models. 24, 36 Additionally, the reduced binding affinity and neutralization must be taken in the context of the entire immune response and the clinical experience.

The vaccines may be clinically effective against variants.

BNT162b2 was found to be effective at preventing COVID-19, hospitalization, and death due to the Alpha and Beta variants in Qatar where nearly all cases of SARS-CoV-2 were due to either of the two variants (Table 3) . 41 The UK experience with BNT162b2 was similar when the Alpha variant was the dominant circulating variant. 42 Additional studies have corroborated these findings. 43, 44 mRNA-1273 has been found to be clinically effective against Another potential benefit of vaccination in persons who are pregnant is maternal transfer of SARS-CoV-2 antibodies from mother to fetus. Assessment of cord blood from mother-neonatal pairs has consistently demonstrated the presence of SARS-CoV-2 IgG. [48] [49] [50] This finding was observed for antibodies after natural infection 48, 49 and vaccination. 50 Mothers also may transfer SARS-CoV-2 antibodies via breastmilk. 50 Although these studies are small, they suggest that maternal transfer of antibodies to the fetus and neonate is a likely benefit of vaccination.

With regards to risks, the teratogenic effects of these vaccines were examined in animal models prior to clinical trials and realworld data are beginning to corroborate these findings. It is also prudent to examine the immunogenicity of these vaccines in pregnant individuals. Data indicate that the immune response to BNT162b2 and mRNA-1273 in persons who are pregnant and lactating is similar to nonpregnant, non-lactating women. 50, 52 At this time, data were unavailable on the immunogenicity of Ad26. States. 56 While it may be compelling to vaccinate only high-risk children, there is limited evidence about which underlying medical conditions might increase the risk for severe illness in children. Among children <18 years old admitted to the hospital for COVID-19, only 42% had one or more underlying high-risk medical condition, with obesity being the most prevalent (37.8%). 57 Therefore, vaccinating children against COVID-19 remains critical.

There is also concern that COVID-19 may become a disease of the young as more adults are vaccinated. According to the American Academy of Pediatrics and Children's Hospital Association, the incidence of disease among pediatrics is increasing each week, with children making up as high as 24% of incident COVID-19 cases in May 2021. 58 Cumulative cases also continue to increase in pediatrics, with percent total cases in May 2021 at 14% compared with <5% in spring 2020. laboratory-confirmed SARS-CoV-2) seven days after the second dose. 59 BNT162b2 was also well tolerated in adolescence receiving the study vaccine, with similar reactogenic effects observed in the 16-25 age group. 59 Additional clinical trials for BNT162b2, mRNA-1273, and Ad26.COV2.S are ongoing in various age groups from 6 months through 17 years ( Table 5 ).

Academy of Pediatrics support co-administration of the COVID-19

vaccine with other routine childhood and adolescent vaccines. 19 Real-world data have corroborated findings from the clinical trials.

Emerging data indicate that immunity is conferred within 2 weeks of vaccination and may last at least 6 months. Data indicate that some vaccines may be effective against SARS-CoV-2 VOC. Finally, populations not included in the original studies may also benefit from vaccination. Combined, these data suggest that the vaccines will be critical in ending the COVID-19 pandemic.

The Society of Infectious Diseases Pharmacists (SIDP) Publications and Podcasts Committee developed the concept for this manuscript, identified expert authors, provided peer review throughout its composition, and approved its final form. The SIDP Board of Directors also reviewed and approved the manuscript at each stage in its development, including its final form.

Emergency use authorization for vaccines explained | FDA

United States Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. Development and licensure of vaccines to prevent COVID-19

Kaiser Family Foundation. KFF COVID-19 vaccine monitor

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19

Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Early evidence of the effect of SARS-CoV-2 vaccine at one medical center

SARS-CoV-2 infection after vaccination in health care workers in California

Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing preprocedural COVID-19 molecular screening

Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers -eight U.S. locations

Asymptomatic and symptomatic SARS-CoV-2 infections after BNT162b2 vaccination in a routinely screened workforce

SARS-CoV-2 transmission from people without COVID-19 symptoms

Postlicensure evaluation of COVID-19 vaccines

Reactogenicity following receipt of mRNA-based COVID-19 vaccines

First month of COVID-19 vaccine safety monitoring -United States

Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine -United States

Centers for Disease Control and Prevention Interim clinical considerations for use of COVID-19 vaccines currently authorized in the United States

Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination

Pfizer Inc Pfizer and BioNTech confirm high efficacy and no serious safety concerns through up to six months following second dose in updated topline analysis of landmark COVID-19 vaccine study

Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19

Correlates of protection against SARS-CoV-2 in rhesus macaques

Covid-19 breakthrough infections in vaccinated health care workers

Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays

FDA in brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

C0994-system-letter-COVID-19-vaccination-deployment-planning-30

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study

Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2

Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine

SARS-CoV-2 variant classifications and definitions

Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

Serum neutralizing activity of mRNA-1273 against SARS-CoV-2 variants

Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study

SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant

Effectiveness of COVID-19 vaccines against variants of concern in Ontario

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis

Maternal and neonatal morbidity and mortality among pregnant women with and without COVID-19 infection: the INTERCOVID multinational cohort study

Assessment of maternal and neonatal cord blood SARS-CoV-2 antibodies and placental transfer ratios

Maternal antibody response, neutralizing potency, and placental antibody transfer after severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons

Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women

Age and sex composition in the United States

Multisystem inflammatory syndrome in U.S. children and adolescents

Racial and/or ethnic and socioeconomic disparities of SARS-CoV-2 infection among children

Effects of the COVID-19 pandemic on routine pediatric vaccine ordering and administration -United States

Hospitalization rates and characteristics of children aged <18 years hospitalized with laboratory-confirmed COVID-19 -COVID-NET, 14 states

statelevel data report

Coronavirus (COVID-19) update: FDA authorizes Pfizer-BioNTech COVID-19 vaccine for emergency use in adolescents in another important action in fight against pandemic

Committee on Infectious Diseases. COVID-19 vaccines in children and adolescents

Early clinical trial data and real-world assessment of COVID-19 vaccines. Insights from the Society of Infectious Diseases Pharmacists

The authors declare no conflicts of interest.

https://orcid.org/0000-0003-0921-549X